Insmed Announces Results from Phase 2 Clinical Trial for Treatment Resistant

Insmed Announces Results from Phase 2 Clinical Trial for Treatment Resistant … The randomized, double-blind, placebo-controlled phase 2 clinical trial compared ARIKAYCE (590 mg delivered once daily), added to standard of care treatment, versus standard of care treatment plus placebo,… Continue Reading